IGF::OT::IGF - ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH.

DEFINITIVE CONTRACT won by VENATORX PHARMACEUTICALS INC · work in MALVERN, PA
$48,517,079
RecipientVENATORX PHARMACEUTICALS INC UEI MBBKNBU5DCC6
Award IDHHSN272201600029C
Award amount$48,517,079
Award typeDEFINITIVE CONTRACT
Awarding agencyDepartment of Health and Human Services — National Institutes of Health
NAICS541711 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY
PSCAN12
Set-asideUnrestricted
Start dateSep 19, 2016
End dateMar 31, 2026
Place of performanceMALVERN, PA
Record updatedJul 31, 2026

View the official award record

More awards won by VENATORX PHARMACEUTICALS INC

VENATORX PHARMACEUTICALS, INC.
Department of Health and Human Services · $131,756,814 · Jul 17, 2019
VENATORX PHARMACEUTICALS: ANTIBIOTIC FOR AMR AND BIOTHREAT PATHOGENS
Department of Health and Human Services · $72,141,707 · Sep 27, 2022
PENICILLIN BINDING PROTEINS IGF::OT::IGF
Department of Defense · $14,716,733 · Aug 28, 2017

Our catalog shows awards with a value or ceiling of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.

Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. $0 today for 14 days (card required), then $49.99/month.

Search open bids